Related Experiment Video
Updated: Jul 6, 2026
07:20
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Herceptin-platinum(II) binding complexes: novel cancer-cell-specific agents
Jian Gao1, Ya Guang Liu, Renbin Liu
1Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA. gaojiantamu@yahoo.com
Chemmedchem
|March 28, 2008
Summary
We developed novel Herceptin-platinum(II) complexes that show potent and cancer-cell-specific cytotoxicity against Her2/neu-overexpressing tumors. These targeted agents offer a promising new strategy for cancer therapy.
Area of Science:
- Oncology
- Medicinal Chemistry
- Biotechnology
Background:
- Herceptin (trastuzumab) is a targeted therapy for HER2-positive cancers.
- Platinum(II) compounds are established chemotherapeutic agents.
- Developing targeted platinum-based therapies can improve cancer treatment efficacy and reduce side effects.
Purpose of the Study:
- To synthesize and characterize novel Herceptin-platinum(II) binding complexes.
- To evaluate the stability and cytotoxicity of these complexes.
- To investigate the targeted delivery and therapeutic potential of these agents against cancer cells.
Main Methods:
- Synthesis of Herceptin-platinum(II) complexes (Her-nL1Pt(II)).
- Solution chemistry studies for stability assessment under physiological conditions.
- In vitro cytotoxicity assays on various human cancer cell lines and normal fibroblasts.
- Annexin V apoptosis assays to confirm Herceptin's role.
- Analysis of Bcl-2 gene regulation in treated cancer cells.
Main Results:
- Herceptin-platinum(II) complexes demonstrated stability under physiological conditions.
- The platinum(II) compound L1Pt(II)Cl(2) inhibited cancer cell growth at sub-micromolar concentrations.
- Her-nL1Pt(II) complexes exhibited remarkable cancer-cell-specific cytotoxicity towards Her2/neu-overexpressing cells.
- Apoptosis assays confirmed the role of Herceptin in targeted cell death.
- Enhanced regulation of apoptotic genes (Bcl-2) was observed with Her-nL1Pt(II) complexes.
Conclusions:
- A new series of stable Herceptin-platinum(II) complexes has been developed.
- These targeted agents show promising cancer-cell-specific cytotoxicity, particularly against Her2/neu-overexpressing cancers.
- This study presents a novel approach for developing monoclonal antibody-platinum(II)-based targeted agents for cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...